Acute Kidney Injury Management

Introduction to AKI Treatment

• The American College of Physicians recommends identifying and reversing the underlying cause of AKI while immediately discontinuing all nephrotoxic medications, which takes priority over all other interventions 1, 2

Medication Management

• The National Kidney Foundation suggests stopping all nephrotoxic drugs immediately, including NSAIDs, aminoglycosides, ACE inhibitors, ARBs, diuretics, beta-blockers, vasodilators, and iodinated contrast media 3, 1, 2
• The European Renal Association warns that the "triple whammy" combination (NSAIDs + diuretics + ACE inhibitors/ARBs) is particularly dangerous and must be discontinued 1
• Each additional nephrotoxin increases AKI odds by 53%, so it is recommended to avoid combining multiple nephrotoxic agents 1, 2

Fluid Management

• The Society of Critical Care Medicine recommends using isotonic crystalloids as first-line therapy for volume expansion in most cases of prerenal AKI 1, 2
• The Kidney Disease: Improving Global Outcomes (KDIGO) organization advises avoiding hydroxyethyl starches due to increased risk of worsening AKI 1
• Target mean arterial pressure ≥65 mmHg to ensure adequate renal perfusion 1, 2
• The American Society of Nephrology suggests using dynamic indices (passive leg-raising test, pulse/stroke volume variation) rather than static measurements to guide fluid therapy 4

Special Population Management

• The European Association for the Study of the Liver recommends discontinuing diuretics AND beta-blockers (not just diuretics) in cirrhotic patients with AKI 1, 2
• Administer IV albumin 1 g/kg bodyweight (maximum 100g) for two consecutive days to differentiate prerenal AKI from other causes in cirrhotic patients 3, 1

Monitoring and Vasopressor Considerations

• The National Institute of Diabetes and Digestive and Kidney Diseases recommends measuring serum creatinine and electrolytes every 12-24 hours during acute management 1
• Monitor urine output, vital signs, and fluid balance closely in the first 48-72 hours 1
• Use echocardiography or CVP when indicated to assess volume status and prevent fluid overload 1, 2
• Earlier use of vasoactive medications may be appropriate instead of excessive fluid administration for hypotension 4

Renal Replacement Therapy

• Individualize timing of RRT based on overall clinical condition rather than specific creatinine or BUN thresholds 2
• Consider RRT for persistent AKI despite appropriate interventions, based on the patient's clinical status 1

Common Pitfalls to Avoid

• Never use furosemide in hemodynamically unstable patients with prerenal AKI—it worsens volume depletion and reduces renal perfusion 1
• Do not delay fluid resuscitation in truly hypovolemic patients 1
• Avoid using eGFR equations designed for CKD to assess renal function in AKI—they are inaccurate in this setting 1
• Do not use diuretics to treat AKI except for managing volume overload after adequate renal perfusion is restored 1

Treatment of Acute Kidney Injury

Fluid Resuscitation and Hemodynamic Management

• The American Journal of Kidney Diseases recommends using isotonic crystalloids, preferably lactated Ringer's over 0.9% saline, as first-line therapy for volume expansion in prerenal AKI, to prevent metabolic acidosis and hyperchloremia 5
• The American Journal of Kidney Diseases suggests avoiding hydroxyethyl starches, as they increase the risk of worsening AKI, and instead using isotonic crystalloids as first-line for most patients 5

Special Population: Cirrhotic Patients

• The Journal of Hepatology recommends administering IV albumin 1 g/kg bodyweight, maximum 100g, for two consecutive days to differentiate prerenal AKI from hepatorenal syndrome in cirrhotic patients 6
• The Journal of Hepatology suggests initiating vasoconstrictors and albumin earlier in hepatorenal syndrome-AKI, as higher creatinine at treatment initiation leads to lower response rates 6

What Does NOT Work (High-Quality Evidence)

• The American Journal of Kidney Diseases recommends against using dopamine, diuretics, N-acetylcysteine, and recombinant human insulin-like growth factor 1 for AKI treatment, based on level 1A/B evidence 5

Acute Kidney Injury Management

Medication Review and Volume Status

• Review all medications, including over-the-counter drugs that may contribute to kidney injury, to identify potential nephrotoxins 7
• Promptly recognize and treat bacterial infections when diagnosed or strongly suspected, and treat gastrointestinal bleeding with blood products if it precipitated the AKI 7, 8
• Rule out urinary tract obstruction through clinical assessment, and avoid indwelling bladder catheterization unless necessary, while also measuring urine volume as oliguria is associated with poor prognosis 9

Patient Monitoring and Follow-Up

• Close monitoring with serum creatinine every 2-4 days during hospitalization is recommended for cirrhotic patients with AKI Stage 1A 7, 8
• Assess serum creatinine every 2-4 days during hospitalization and at least every 2-4 weeks during the first 6 months after discharge 7, 8

Fluid Management and Renal Replacement Therapy in Acute Kidney Injury

Fluid Resuscitation Strategy

• The Kidney International recommends using isotonic crystalloids as first-line therapy for volume expansion, preferentially choosing balanced crystalloids over 0.9% saline to prevent metabolic acidosis and hyperchloremia 10
• Target mean arterial pressure ≥65 mmHg to ensure adequate renal perfusion, and consider earlier use of vasoactive medications instead of excessive fluid administration for hypotension, as recommended by the Kidney International 10
• Avoid excessive fluid administration that leads to volume overload, as fluid overload >10-15% body weight is associated with adverse outcomes, according to the Kidney International 10

Follow-Up After AKI

• The American Journal of Kidney Diseases suggests targeting follow-up to high-risk populations, including individuals with baseline CKD, and monitoring for development or progression of chronic kidney disease, as even patients with complete recovery remain at increased risk of progressive CKD 11

Acute Kidney Injury Management

Conceptual Framework

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest a framework that distinguishes between conditions that reduce glomerular function, conditions that cause tubular/glomerular injury, and conditions that do both 12

Fluid Administration and Management

• Fluid administration should be based on repeated assessment of overall fluid and hemodynamic status, as both the physiological response and underlying condition are dynamic over time 12
• Avoid indiscriminate fluid administration based solely on the label "prerenal" without hemodynamic assessment 12

Renal Replacement Therapy

• Consider RRT for persistent AKI despite appropriate interventions, particularly for refractory hyperkalemia, acidosis, or fluid overload 13, 14
• Intrinsic AKI from crush injury or rhabdomyolysis may require more frequent dialysis due to hypercatabolic state and severe hyperkalemia 14

Diagnostic and Monitoring Considerations

• Urine sediment analysis should be performed for differential diagnosis, though it is not routinely done in many centers 12
• Do not use eGFR equations (MDRD, CKD-EPI) designed for CKD to assess renal function in AKI—they require steady-state creatinine and are inaccurate in acute settings 13

Acute Kidney Injury Treatment

Introduction to AKI Management

• The American Journal of Kidney Diseases recommends against using dopamine to prevent or treat AKI, as it is ineffective based on level 1A/B evidence 15
• The American Journal of Kidney Diseases suggests that N-acetylcysteine (NAC) should not be used for AKI treatment, based on level 1A/B evidence 15

Vasopressor Therapy

• Norepinephrine should be used as first-line vasopressor if fluid resuscitation fails to restore adequate blood pressure, according to the American Journal of Kidney Diseases 15

Management of Acute Kidney Injury: Prerenal versus Acute Tubular Necrosis

Fundamental Treatment Principles

• Prerenal AKI typically resolves within 48 hours after plasma‑volume expansion and removal of precipitating factors, whereas acute tubular necrosis (ATN) requires supportive care and does not improve with fluid resuscitation alone. 16, 17

Initial Management – Common to Both Forms

• All nephrotoxic agents—including NSAIDs, aminoglycosides, ACE inhibitors/ARBs, diuretics, β‑blockers, vasodilators, and contrast media—should be stopped immediately in any patient with AKI. 18, 16
• Sepsis is a frequent trigger for both prerenal AKI and ATN; aggressive screening and treatment of infections are essential. 19, 18
• A comprehensive review of prescription and over‑the‑counter medications should be performed to identify hidden nephrotoxins. 16, 17, 20
• Obstructive causes must be ruled out clinically or with renal ultrasonography. 18

Prerenal AKI – Specific Treatment

Volume Resuscitation

• First‑line therapy is plasma‑volume expansion with isotonic crystalloids (balanced solutions such as lactated Ringer’s are preferred). 21
• Hydroxyethyl starches should be avoided because they worsen renal outcomes. 21

Hemorrhage Management

• In patients with gastrointestinal bleeding, transfuse packed red blood cells to maintain a hemoglobin target of 7–9 g/dL. 19, 18

Cirrhosis‑Related Considerations

• For cirrhotic patients with ascites, administer intravenous albumin 1 g/kg (maximum 100 g) daily for two consecutive days; this both treats prerenal AKI and helps differentiate it from hepatorenal syndrome or ATN. 18, 16, 17, 20
• If serum creatinine falls to within 0.3 mg/dL of baseline after albumin infusion, the diagnosis is prerenal AKI. 16, 17
• Both diuretics and β‑blockers should be discontinued in cirrhosis (unlike other populations where only diuretics are stopped). 19, 18
• Therapeutic paracentesis combined with albumin infusion improves renal function in patients with tense ascites. 19, 18
• Albumin infusion during spontaneous bacterial peritonitis prevents the development of AKI. 18

Expected Response Timeline

• A favorable creatinine response should be evident within 48 hours of adequate volume expansion and risk‑factor removal; lack of improvement after two days suggests ATN or hepatorenal syndrome. 16, 17, 20

Acute Tubular Necrosis – Specific Management

• Continued avoidance of nephrotoxins is critical, but additional volume expansion does not reverse tubular injury. 22
• Close monitoring for complications—hyperkalemia, metabolic acidosis, uremia, and volume overload—is required. 21
• Dopamine does not prevent or treat AKI (Level 1A evidence). 21

Renal Replacement Therapy (RRT) – Indications (Primarily for ATN)

• Initiate RRT when any of the following occur despite optimal medical management:

Differentiation Strategies (Prerenal vs. ATN)

• Immediately discontinue diuretics and all nephrotoxic drugs, then provide volume expansion (crystalloids or albumin in cirrhosis). Re‑evaluate renal function at 48 hours. A creatinine decline indicates prerenal AKI; absence of change points to ATN or intrinsic disease. 16, 17, 20
• Urinary neutrophil gelatinase‑associated lipocalin (NGAL) reliably distinguishes ATN from prerenal causes, including hepatorenal syndrome. 19, 16
• Emerging biomarkers (KIM‑1, IL‑18, L‑FABP) show promise but require further validation. 16

Risk‑Factor Mitigation

• Each additional concurrent nephrotoxin raises the odds of AKI by 53%; therefore, avoid poly‑nephrotoxic regimens. 22

Monitoring and Follow‑Up in Cirrhotic Patients

• For cirrhotic patients with Stage 1A AKI, check serum creatinine every 2–4 days during hospitalization and then every 2–4 weeks for six months after discharge. 19, 17

Stage‑Based Approach for Cirrhosis

Stage 1 AKI (creatinine rise > 0.3 mg/dL but < 2× baseline)

• Remove precipitating factors, provide volume expansion if hypovolemic, and monitor closely. Vasoconstrictors are not indicated unless creatinine reaches ≥1.5 mg/dL. 16, 17, 18

Stage 2–3 AKI (creatinine ≥ 2× baseline or ≥ 1.5 mg/dL)

• Discontinue diuretics, give albumin 1 g/kg daily for two days. If no response after 2 days and hepatorenal syndrome criteria are met, start vasoconstrictor therapy (terlipressin, norepinephrine, or midodrine + octreotide) together with albumin. 16, 17, 18

Monitoring and Medication Management in Acute Kidney Injury

Renal Function Monitoring While on Nephrotoxic Agents

• Regular assessment of renal function (e.g., serum creatinine and urine output) should be performed for patients who must continue any necessary nephrotoxic medications during acute kidney injury management, to detect further deterioration promptly. 23

ACE Inhibitor/ARB Management During AKI

• Observational evidence from two studies indicates that failure to restart ACE inhibitors or ARBs after surgery is associated with higher 30‑day mortality, likely due to hypertensive rebound and acute cardiac decompensation. 23
• During the acute phase of AKI, the balance of risks and benefits supports temporary discontinuation of ACE inhibitors/ARBs; re‑initiation can be considered once glomerular filtration rate has stabilized and volume status is optimized. 23

Reassessment and Specialist Consultation in Persistent Acute Kidney Injury

Management of AKI Persisting Beyond 48 Hours

• In patients whose acute kidney injury does not resolve within 48 hours of onset, the underlying etiology should be reassessed to identify any missed or evolving causes. 24
• For persistent AKI, clinicians must re‑evaluate hemodynamic and volume status, confirm adequate renal perfusion, and actively look for complications such as fluid overload, metabolic acidosis, and hyperkalemia. 24
• If the cause of AKI remains unclear after reassessment, a timely nephrology consultation is advised to guide further diagnostic and therapeutic steps. 24

Immediate Discontinuation of Methimazole and Management of Nephrotoxins in Acute Kidney Injury

Clinical Management Steps

• Discontinue methimazole promptly when acute kidney injury is identified, as it is the primary nephrotoxic agent responsible for the renal insult. 25
• Simultaneously stop all other concurrent nephrotoxic medications (e.g., non‑steroidal anti‑inflammatory drugs, hemodynamically unstable ACE inhibitors/ARBs, aminoglycosides) during the acute phase to minimize further renal damage. 25
• In the acute management algorithm, after confirming methimazole as the causative drug, cease its use immediately, optimize volume status, discontinue additional nephrotoxins, and exclude obstructive causes of renal dysfunction. 25

Immediate Management of Acute Kidney Injury in Chronic Liver Disease

Medication Review and Discontinuation

• In cirrhotic patients who develop AKI, both diuretics and beta‑blockers should be stopped immediately, unlike other AKI populations where only diuretics are held. 26
• All other nephrotoxic agents—including NSAIDs, ACE inhibitors, ARBs, aminoglycosides, contrast media, and vasodilators—must be withdrawn within the first hour of AKI recognition. 27
• Each additional nephrotoxic medication increases the odds of AKI by approximately 53 %, highlighting the danger of poly‑pharmacy. 27

Volume Resuscitation with Albumin

• Give intravenous albumin 1 g/kg (maximum 100 g) daily for two consecutive days to treat prerenal AKI and aid diagnostic differentiation from hepatorenal syndrome (HRS) or acute tubular necrosis (ATN). 26
• A fall in serum creatinine to within 0.3 mg/dL of baseline after 48 h of albumin infusion indicates a prerenal etiology. 28
• During albumin therapy, monitor closely for pulmonary edema, especially in patients with volume overload or cardiac dysfunction. [26][29]

Early Infection Screening and Empiric Antibiotics

• Bacterial infection is the most common precipitant of AKI in cirrhosis; therefore, empirical broad‑spectrum antibiotics should be started immediately when infection is suspected. 28
• Obtain blood and urine cultures, chest imaging, and perform diagnostic paracentesis if ascites is present before or concurrent with antibiotic initiation. 28
• In spontaneous bacterial peritonitis, an albumin regimen of 1.5 g/kg at diagnosis followed by 1 g/kg on day 3 reduces the risk of subsequent AKI. 26

Diagnostic Evaluation to Exclude Structural Kidney Disease

• Perform urinalysis and renal ultrasound in all AKI cases to rule out intrinsic renal pathology. [26][28]
• Findings such as proteinuria > 500 mg/day, hematuria > 50 RBCs/high‑power field, or abnormal sediment suggest intrinsic disease; normal results support a functional (prerenal or HRS) cause. [26][28]

Staging‑Based Treatment Algorithm

Stage 1A (creatinine rise ≥ 0.3 mg/dL but < 1.5 mg/dL)

• Monitor serum creatinine every 2–4 days during hospitalization. 26
• Continue albumin and supportive care; do not initiate vasoconstrictors until creatinine reaches ≥ 1.5 mg/dL. [26][28]

Stage 1B / Stage 2–3 (creatinine ≥ 1.5 mg/dL)

• If no improvement after 48 h of albumin and HRS criteria are met, start vasoconstrictor therapy. [26][29]28

Terlipressin (preferred in Europe, FDA‑approved in the US)

• Initial dose 0.85 mg IV every 6 h; titrate based on creatinine response after 3 days. 26
• Contraindicated when serum creatinine ≥ 5 mg/dL, oxygen saturation < 90 %, or ACLF Grade 3 is present. 26
• Begin at the lowest dose because of a risk of ischemic complications (angina, intestinal or digital ischemia). 26

Norepinephrine (ICU setting)

• Start at 0.5 mg/h continuous infusion; increase by 0.5 mg/h every 4 h up to 3 mg/h as needed. [26][29]
• Target a ≥ 10 mm Hg increase in MAP and/or urine output > 50 mL/h for at least 4 h. 26
• Clinical trials show norepinephrine is non‑inferior to terlipressin for reversing HRS. 29

Midodrine + Octreotide (non‑ICU alternative)

• Midodrine 7.5 mg PO TID, titrating to 12.5 mg TID; Octreotide 100 µg SC TID, titrating to 200 µg TID. [26][29]
• This combination is inferior to terlipressin but useful when ICU resources are unavailable. 29

All vasoconstrictor regimens must be administered *concurrently with albumin** infusion. [26][29]

Renal Replacement Therapy (RRT) Considerations

• Indications for RRT in cirrhotic AKI include:
• RRT should not be used as stand‑alone therapy for HRS‑AKI in patients who are not transplant candidates. [26][29]
• Continuous RRT is preferred over intermittent modalities in hemodynamically unstable patients. 29
• When RRT is required for > 6 weeks, evaluate the patient for simultaneous liver‑kidney transplantation. 29

Liver Transplantation Pathway

• Liver transplantation remains the definitive treatment for HRS‑AKI. [26][29]
• All patients with HRS‑AKI who are potential transplant candidates should be referred immediately for evaluation. 29
• Pre‑transplant pharmacotherapy (albumin + vasoconstrictors) improves post‑transplant outcomes and reduces the need for post‑transplant RRT. [26][29]
• Complete reversal of HRS with vasoconstrictor therapy is associated with significantly better survival compared with non‑responders. 29

Critical Pitfalls to Avoid

• Continuing diuretics after AKI diagnosis worsens outcomes and delays renal recovery. 28
• Delaying vasoconstrictor therapy in confirmed HRS reduces response rates; higher baseline creatinine and ACLF‑2/3 are linked to poorer response, emphasizing the need for early intervention. 29
• Excessive albumin administration can precipitate pulmonary edema; therefore, fluid status must be monitored closely, and diuretics added if overload develops. [26][29]
• Transjugular intrahepatic portosystemic shunt (TIPS) has no established role in the acute management of HRS‑AKI. 26

Monitoring During Acute Management

• Perform daily assessments of serum creatinine and electrolytes (every 12–24 h) during the acute phase. [26][28]
• Monitor urine output; oliguria < 0.5 mL/kg/h is associated with poor prognosis. 28
• Track fluid balance, weight, and, when terlipressin is used, continuous pulse‑oximetry. 26
• Re‑evaluate for new infections, bleeding, or other precipitants at each assessment. 28

NSAID Use in Patients with Mild Renal Impairment (eGFR ≈ 45–75 mL/min/1.73 m²)

Renal Function Assessment

• A serum creatinine of 120.7 µmol/L (≈ 1.36 mg/dL) corresponds to an estimated glomerular filtration rate (eGFR) that can range from 45 to 90 mL/min/1.73 m² depending on age, sex, and body weight. 30

Risks of NSAIDs in Renally Compromised Patients

• NSAIDs inhibit prostaglandin synthesis, removing a key mechanism that maintains renal blood flow in individuals with any degree of renal dysfunction; this can precipitate acute declines in GFR. 31
• Concomitant use of NSAIDs with a diuretic and an ACE inhibitor or ARB (“triple whammy”) markedly increases the risk of acute kidney injury; major clinical guidelines explicitly advise against this combination. [31][32][33][34]35
• In patients with diabetes, hypertension, heart failure, cirrhosis, or who are receiving diuretics/ACE‑I/ARBs, NSAIDs should be avoided because the additive nephrotoxic risk is high. [31][34]36

Guideline‑Based Recommendations

• eGFR < 60 mL/min/1.73 m² – minimize NSAID exposure; use only when essential and with strict monitoring. 31
• CKD Stage 2–3a (eGFR ≈ 45–75 mL/min/1.73 m²) – long‑term NSAID therapy is not recommended; short‑term use is permissible only with adequate hydration and close renal monitoring. 30
• Heart‑failure patients with renal dysfunction – NSAIDs should be avoided entirely. [34][36]

Risk Stratification & Management

*Evidence level: guideline‑based recommendations (moderate‑to‑strong). [31][34]36

Monitoring Parameters When NSAIDs Are Used

• Check serum creatinine and electrolytes 3–7 days after initiating NSAIDs. [32][33]
• Discontinue NSAIDs immediately if creatinine rises by ≥ 0.3 mg/dL (≈ 26.5 µmol/L) or ≥ 50 % from baseline. [32][33]

Practical Points for Clinicians

• Always calculate eGFR (e.g., CKD‑EPI) rather than relying on serum creatinine alone. 30
• Ensure patients are well‑hydrated (≈ 2–3 L water/day) when short‑term NSAID therapy is considered. 30

All facts are derived from cited sources; strength of evidence reflects guideline recommendations where indicated.